查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081993

再生醫學市場：全球市場按產品類型、原料、應用領域和最終用戶分類的預測－2026-2032年

Regenerative Medicine Market by Product Type, Source, Application Areas, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，再生醫學市場將成長至 1,183.3 億美元，複合年成長率為 21.64%。

主要市場統計數據
基準年 2025 300.3億美元
預計年份：2026年 363.9億美元
預測年份：2032年 1183.3億美元
複合年成長率 (%) 21.64%

再生醫學市場概覽

再生醫學正從一個充滿前景的實驗領域發展成為一個受監管、以實證醫學為基礎的醫療保健領域，涵蓋細胞療法、基因療法、組織工程、幹細胞療法、生物材料、細胞外囊泡平台和先進的傷口修復技術。這一領域的發展得益於已獲批准的先進療法、不斷擴展的臨床試驗項目以及來自美國FDA、歐洲藥品管理局（EMA）、日本PMDA和其他國家監管機構等監管機構日益嚴格的生產標準。

再生醫學前景的變革性變化

再生醫學領域正從個人化、單中心開發轉向產業化平台。自體CAR-T療法已展現出基因修飾細胞的臨床和商業性潛力。同時，異體細胞療法、體內基因編輯、誘導多功能細胞（iPS細胞）平台、細胞外囊泡療法和3D生物列印正在重新定義人們對可擴展性、一致性和可重複性的期望。

人工智慧對再生醫學的累積影響

人工智慧 (AI) 正在對再生醫學的研究與開發、生產和商業化等各個領域產生累積影響。 AI 驅動的分析技術透過輔助標靶發現、載體設計、細胞表現型預測、供體選擇、基於影像的品管、生物標記識別和臨床前模型解讀，幫助開發人員縮短迭代周期並提高可重複性。

關鍵區域洞察：再生醫學的全球應用

北美憑藉其FDA的監管、對生物醫學領域的大力投入、學術醫療中心、專業的合約研發生產（CDMO）能力以及對細胞和基因療法的早期應用，仍然是再生醫學領域的領先地區。美國透過先進療法認定（ATD）、治療中心網路和生物製造領域的投資，在臨床應用方面處於領先地位；而加拿大則透過其幹細胞研究舉措、公私合營以及醫院創新做出貢獻。

主要區域集團概況：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協，再生醫學正透過醫療旅遊、醫院現代化、生物製造以及對細胞治療服務日益成長的需求而加強。新加坡尤其發揮區域生物醫學監管、轉化研究和臨床創新中心的作用。海灣合作理事會（GCC）正將再生醫學納入國家醫療衛生轉型議程，並增加對專科醫院、基因組學計畫、數位醫療基礎設施和先進治療能力的投資。

重點國家洞察：優先再生醫學市場

憑藉FDA批准的細胞和基因療法、專業的治療中心、先進的臨床檢測基礎設施以及強大的生物技術生態系統，美國引領再生醫學的商業化進程。加拿大透過覆蓋全國的研究網路、幹細胞科學和先進製造舉措，為再生醫學的發展提供支援；墨西哥則致力於提升專科醫療、移植技術和跨境醫療需求的能力。巴西是拉丁美洲最主要的再生醫學市場，這得益於大學附屬醫院、公共研究機構、細胞療法研究以及大規模的患者群體，這些患者群體存在著巨大的未滿足醫療需求。

再生醫學領域領導者使用的實用建議

產業領導者應優先考慮平台可擴展性，而非單一資產開發，為此應投資於封閉式系統生產、檢驗的療效檢測、自動化品管、標準化的可比性方案以及專用低溫運輸網路。儘早與監管機構和保險公司合作至關重要，以便使臨床試驗終點、持久性證據、伴隨診斷、患者隨訪和上市後計劃與准入要求保持一致。

調查方法

本研究方法基於二手資料研究，包括監管指南、臨床實驗室註冊資訊、同行評審文獻、衛生機構出版刊物、專利趨勢、最新報銷方案、學術團體資料以及廣泛認可的行業資料庫。研究結果被整合，以確定每種再生醫學模式的需求促進因素、技術發展、區域趨勢、競爭重點、生產限制、證據要求和商業化障礙。

結論

再生醫學已進入關鍵階段，科學突破必須與生產規範、監管信譽、倫理管治和支付方信心相平衡。細胞療法、基因療法、組織工程、幹細胞療法、細胞外囊泡和生物材料正在融合形成一個更廣泛、更先進的治療生態系統，重點在於實現持續的治療效果、個人化醫療和恢復生物功能。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 再生醫學市場：依產品類型分類

  • 細胞療法
    • 非幹細胞療法
      • 免疫細胞
      • 樹突狀細胞
      • 自然殺手（NK）細胞
      • T細胞
      • 非免疫細胞
    • 幹細胞療法
  • 細胞外/無細胞療法
  • 基因治療
    • 基因編輯技術
    • 基因轉移載體
      • 非病毒載體
      • 病毒載體
    • 基於RNA和DNA的療法
  • 組織工程
    • 生物材料
      • 天然生物材料
      • 合成生物材料
    • 生長因子和細胞激素
    • 骨骼

第8章：再生醫學市場：依原料分類

  • 同種異體移植
  • 本土種植
  • 合成

第9章 再生醫學市場：依應用領域分類

  • 心血管系統
    • 血管新生與再生
    • 先天性心臟疾病的治療
    • 心臟瓣膜置換術
    • 心肌梗塞的治療
  • 皮膚科
    • 美容護理
    • 燒傷治療
    • 慢性傷口的治療
  • 糖尿病
    • BETA細胞移植
    • 胰島細胞再生
  • 神經病學
    • 阿茲海默症治療
    • 多發性硬化症的治療
    • 帕金森氏症治療
    • 脊髓損傷修復
    • 中風復健
  • 腫瘤學
    • 癌症免疫療法
    • 腫瘤消融
  • 眼科
    • 角膜修復
    • 視網膜再生
  • 整形外科和肌肉骨骼系統
    • 骨再生
    • 軟骨修復
    • 肌腱修復

第10章 再生醫學市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 醫院和診所
  • 製藥和生物技術公司

第11章 再生醫學市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 再生醫學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 再生醫學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Novartis AG
  • Gilead Sciences, Inc.
  • Stryker Corporation
  • Johnson & Johnson Services, Inc.
  • FUJIFILM Holdings Corporation
  • Zimmer Biomet Holdings, Inc.
  • Merck KGaA
  • Integra LifeSciences Holdings Corporation
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • AGC Inc.
  • Organogenesis Holdings Inc.
  • CRISPR Therapeutics AG
  • CMIC HOLDINGS Co., LTD.
  • JCR Pharmaceuticals Co., Ltd.
  • Sysmex Corporation
  • Vericel Corporation
  • Orchard Therapeutics PLC
  • STEMPEUTICS RESEARCH PVT LTD
  • REPROCELL Inc.
  • Mesoblast Limited
  • 4D Molecular Therapeutics, Inc.
  • Abeona Therapeutics Inc.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Bayer AG
  • Fate Therapeutics, Inc.
  • NervGen Pharma Corp.
  • Pluri BIoTech Ltd.
  • Regentis Biomaterials Ltd.
  • RepliCel Life Sciences Inc.
  • SanBio Co, Ltd.
  • SMSbIoTech, Inc.
  • Sumitomo Pharma Co., Ltd.
  • Tenaya Therapeutics, Inc.
  • Voyager Therapeutics Inc.
Product Code: MRR-430D42AA0F5B

The Regenerative Medicine Market is projected to grow by USD 118.33 billion at a CAGR of 21.64% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.03 billion
Estimated Year [2026] USD 36.39 billion
Forecast Year [2032] USD 118.33 billion
CAGR (%) 21.64%

Regenerative Medicine Market Introduction

Regenerative medicine is moving from experimental promise to a regulated, evidence-driven healthcare category spanning cell therapy, gene therapy, tissue engineering, stem cell therapy, biomaterials, extracellular vesicle platforms, and advanced wound-repair technologies. The field is being shaped by authorized advanced therapies, expanding clinical-trial pipelines, and stronger manufacturing standards under agencies such as the U.S. FDA, European Medicines Agency, Japan's PMDA, and other national regulators.

Demand is supported by the clinical burden of cancer, rare genetic disorders, musculoskeletal injuries, cardiovascular disease, diabetes, neurodegenerative conditions, and chronic wounds. Industry momentum is increasingly tied to scalable GMP manufacturing, durable clinical outcomes, real-world evidence, cold-chain logistics, reimbursement readiness, and the ability to convert biological innovation into reproducible, patient-accessible therapies.

Transformative Shifts in the Regenerative Medicine Landscape

The regenerative medicine landscape is shifting from bespoke, single-site development toward industrialized platforms. Autologous CAR-T therapies demonstrated the clinical and commercial potential of engineered cells, while allogeneic cell therapy, in vivo gene editing, induced pluripotent stem cell platforms, extracellular vesicle therapeutics, and 3D bioprinting are reshaping expectations for scalability, consistency, and repeatability.

Regulatory pathways are also maturing. Accelerated designations, hospital exemption models, ATMP rules in Europe, and regenerative medicine advanced therapy pathways in the United States are helping sponsors align evidence generation with patient access. At the same time, regulators are intensifying oversight of unproven stem cell interventions, making validated potency assays, traceable supply chains, standardized release criteria, and long-term safety monitoring critical differentiators.

Cumulative Impact of Artificial Intelligence in Regenerative Medicine

Artificial intelligence is becoming a cumulative force across regenerative medicine research, development, manufacturing, and commercialization. AI-enabled analytics support target discovery, vector design, cell phenotype prediction, donor selection, image-based quality control, biomarker identification, and preclinical model interpretation, helping developers shorten iteration cycles while improving reproducibility.

The largest impact is emerging in manufacturing and clinical evidence generation. Machine learning can detect batch variability, predict process deviations, optimize bioreactor conditions, and support digital release testing. In clinical programs, AI helps stratify patients, analyze multimodal outcomes, identify safety signals, and strengthen real-world evidence; however, adoption must remain aligned with data integrity, model validation, privacy, cybersecurity, and explainability requirements.

Key Regional Insights: Global Regenerative Medicine Adoption

North America remains a leading region for regenerative medicine because of FDA oversight, deep biomedical financing, academic medical centers, specialized contract development and manufacturing capacity, and early adoption of cell and gene therapies. The United States anchors clinical translation through advanced therapy designations, treatment-center networks, and biomanufacturing investment, while Canada contributes through stem cell research networks, public-private biomanufacturing initiatives, and hospital-based innovation.

Europe is characterized by the European Medicines Agency's advanced therapy medicinal product framework, strong public research funding, and established biopharma clusters across Germany, France, Italy, Spain, and the United Kingdom. The region benefits from coordinated clinical research, transplantation expertise, and structured pharmacovigilance requirements, although access pathways and reimbursement decisions remain country-specific. Asia-Pacific is advancing rapidly through Japan's conditional and time-limited approval environment for regenerative medical products, China's large clinical-trial base, South Korea's cell therapy expertise, India's expanding biomanufacturing capacity, and Australia's translational research infrastructure.

Latin America is gaining relevance through Brazil and Mexico, where specialized hospitals, oncology needs, academic cell therapy research, and local manufacturing ambitions are driving interest. The Middle East is investing in precision medicine, genomics, and advanced healthcare infrastructure, particularly across GCC markets that are building specialized care models. Africa remains earlier-stage but presents long-term opportunity in regenerative wound care, sickle cell disease, burn treatment, and capacity-building partnerships supported by clinical training, ethical governance, and sustainable supply chains.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are strengthening regenerative medicine through medical tourism, hospital modernization, biomanufacturing interest, and growing demand for cell therapy services, with Singapore providing a regional hub for biomedical regulation, translational research, and clinical innovation. The GCC is positioning regenerative medicine within national healthcare transformation agendas, supported by specialist hospitals, genomics programs, digital health infrastructure, and investment in advanced therapy capabilities.

The European Union offers one of the most defined regulatory environments through ATMP governance, centralized marketing authorization, clinical-trial harmonization, pharmacovigilance obligations, and cross-border research funding. BRICS countries provide scale, patient diversity, and manufacturing potential, with China, India, and Brazil especially important for clinical development, local production, and cost-efficient process innovation. G7 markets remain central to reimbursement standards, intellectual property protection, clinical guideline development, and premium therapy adoption, while NATO-aligned economies contribute through resilient supply chains, biomedical security priorities, and harmonized research collaboration for advanced therapeutic platforms.

Key Country Insights: Priority Regenerative Medicine Markets

The United States leads commercialization through FDA-authorized cell and gene therapies, specialized treatment centers, advanced clinical-trial infrastructure, and a strong biotechnology ecosystem. Canada supports regenerative medicine through national research networks, stem cell science, and advanced manufacturing initiatives, while Mexico is developing capacity around specialty care, transplantation expertise, and cross-border healthcare demand. Brazil is Latin America's most visible regenerative medicine market, supported by academic hospitals, public research institutions, cell therapy studies, and a large patient base with high unmet need.

In Europe, the United Kingdom remains a translational leader with strong clinical-trial infrastructure and advanced therapy manufacturing programs; Germany combines engineering, biologics manufacturing, hospital depth, and regulatory discipline; France benefits from public research and biotherapy expertise; Italy and Spain contribute through ATMP clinical networks, transplantation experience, and specialist hospitals; and Russia maintains scientific activity in cell therapy and biomedical research despite geopolitical constraints affecting international collaboration and supply access.

In Asia-Pacific, China has one of the world's most active cell and gene therapy pipelines, supported by hospital-led research, regulatory reforms, and domestic manufacturing capabilities. India is expanding affordable biomanufacturing, stem cell research, and specialty clinical services under evolving regulatory supervision. Japan benefits from a supportive regenerative medicine framework and strong iPSC science, Australia provides high-quality translational research and clinical governance, and South Korea remains a major innovator in stem cell therapy, cell processing, and advanced therapy commercialization.

Actionable Recommendations for Regenerative Medicine Leaders

Industry leaders should prioritize platform scalability over single-asset development by investing in closed-system manufacturing, validated potency assays, automated quality control, standardized comparability protocols, and fit-for-purpose cold-chain networks. Early engagement with regulators and payers is essential to align trial endpoints, durability evidence, companion diagnostics, patient follow-up, and post-authorization commitments with access requirements.

Organizations should also build AI governance, data interoperability, model validation, and cybersecurity into development programs from the outset. Partnerships with academic medical centers, contract manufacturers, hospitals, donor networks, and patient registries can accelerate recruitment and real-world evidence generation. Commercial strategies should include value-based contracting, site-of-care readiness, clinician education, transparent patient safety communication, and clear evidence plans for long-term outcomes.

Research Methodology

Research methodology is grounded in secondary research from regulatory guidance, clinical-trial registries, peer-reviewed literature, health agency publications, patent activity, reimbursement updates, scientific society materials, and recognized industry databases. Findings were synthesized to identify demand drivers, technology shifts, regional dynamics, competitive priorities, manufacturing constraints, evidence requirements, and commercialization barriers across regenerative medicine modalities.

The methodology emphasizes triangulation across scientific, regulatory, and commercial sources. Market signals were evaluated through therapy modality, clinical maturity, manufacturing readiness, geographic adoption, policy environment, quality-control expectations, and evidence-generation requirements. Insights were reviewed for consistency with verified public information and are presented in a leader-focused format for strategic decision-making without relying on market sizing, market share, or forecasting.

Conclusion

Regenerative medicine is entering a decisive phase in which scientific breakthroughs must be matched with manufacturing discipline, regulatory credibility, ethical governance, and payer confidence. Cell therapy, gene therapy, tissue engineering, stem cell therapy, extracellular vesicles, and biomaterials are converging into a broader advanced-therapy ecosystem focused on durable outcomes, personalized care, and restoration of biological function.

Organizations that combine validated science, AI-enabled operations, scalable production, robust real-world evidence, and transparent safety monitoring will be best positioned to capture opportunity in regenerative medicine. The next stage will favor developers that move beyond innovation narratives and deliver safe, reproducible, accessible, and clinically meaningful regenerative therapies for patients with high unmet medical need.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Regenerative Medicine Market, by Product Type

  • 7.1. Cell Therapy
    • 7.1.1. Non-Stem Cell-Based Therapy
      • 7.1.1.1. Immune Cells
      • 7.1.1.1.1. Dendritic Cells
      • 7.1.1.1.2. Natural Killer (NK) Cells
      • 7.1.1.1.3. T Cells
      • 7.1.1.2. Non-immune Cells
    • 7.1.2. Stem Cell-Based Therapy
  • 7.2. Extracellular & Acellular Therapies
  • 7.3. Gene Therapy
    • 7.3.1. Gene Editing Technologies
    • 7.3.2. Gene Transfer Vectors
      • 7.3.2.1. Non-Viral Vectors
      • 7.3.2.2. Viral Vectors
    • 7.3.3. RNA & DNA-Based Therapies
  • 7.4. Tissue Engineering
    • 7.4.1. Biomaterials
      • 7.4.1.1. Natural Biomaterials
      • 7.4.1.2. Synthetic Biomaterials
    • 7.4.2. Growth Factors & Cytokines
    • 7.4.3. Scaffolds

8. Regenerative Medicine Market, by Source

  • 8.1. Allogeneic
  • 8.2. Autologous
  • 8.3. Synthetic

9. Regenerative Medicine Market, by Application Areas

  • 9.1. Cardiovascular
    • 9.1.1. Angiogenesis & Vascular Regeneration
    • 9.1.2. Congenital Heart Defect Repair
    • 9.1.3. Heart Valve Replacement
    • 9.1.4. Myocardial Infarction Treatment
  • 9.2. Dermatology
    • 9.2.1. Aesthetic Procedures
    • 9.2.2. Burn Treatment
    • 9.2.3. Chronic Wound Healing
  • 9.3. Diabetes
    • 9.3.1. Beta Cell Transplantation
    • 9.3.2. Islet Cell Regeneration
  • 9.4. Neurology
    • 9.4.1. Alzheimer's Treatment
    • 9.4.2. Multiple Sclerosis Therapy
    • 9.4.3. Parkinson's Therapy
    • 9.4.4. Spinal Cord Injury Repair
    • 9.4.5. Stroke Recovery
  • 9.5. Oncology
    • 9.5.1. Cancer Immunotherapy
    • 9.5.2. Tumor Ablation
  • 9.6. Ophthalmology
    • 9.6.1. Corneal Repair
    • 9.6.2. Retinal Regeneration
  • 9.7. Orthopedic & Musculoskeletal
    • 9.7.1. Bone Regeneration
    • 9.7.2. Cartilage Repair
    • 9.7.3. Tendon Repair

10. Regenerative Medicine Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Hospitals & Clinics
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Regenerative Medicine Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Regenerative Medicine Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Regenerative Medicine Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Novartis AG
  • 15.2. Gilead Sciences, Inc.
  • 15.3. Stryker Corporation
  • 15.4. Johnson & Johnson Services, Inc.
  • 15.5. FUJIFILM Holdings Corporation
  • 15.6. Zimmer Biomet Holdings, Inc.
  • 15.7. Merck KGaA
  • 15.8. Integra LifeSciences Holdings Corporation
  • 15.9. AbbVie Inc.
  • 15.10. F. Hoffmann-La Roche Ltd.
  • 15.11. AGC Inc.
  • 15.12. Organogenesis Holdings Inc.
  • 15.13. CRISPR Therapeutics AG
  • 15.14. CMIC HOLDINGS Co., LTD.
  • 15.15. JCR Pharmaceuticals Co., Ltd.
  • 15.16. Sysmex Corporation
  • 15.17. Vericel Corporation
  • 15.18. Orchard Therapeutics PLC
  • 15.19. STEMPEUTICS RESEARCH PVT LTD
  • 15.20. REPROCELL Inc.
  • 15.21. Mesoblast Limited
  • 15.22. 4D Molecular Therapeutics, Inc.
  • 15.23. Abeona Therapeutics Inc.
  • 15.24. Astellas Pharma Inc.
  • 15.25. Athersys, Inc.
  • 15.26. Bayer AG
  • 15.27. Fate Therapeutics, Inc.
  • 15.28. NervGen Pharma Corp.
  • 15.29. Pluri Biotech Ltd.
  • 15.30. Regentis Biomaterials Ltd.
  • 15.31. RepliCel Life Sciences Inc.
  • 15.32. SanBio Co,Ltd.
  • 15.33. SMSbiotech, Inc.
  • 15.34. Sumitomo Pharma Co., Ltd.
  • 15.35. Tenaya Therapeutics, Inc.
  • 15.36. Voyager Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL REGENERATIVE MEDICINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL REGENERATIVE MEDICINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL REGENERATIVE MEDICINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL REGENERATIVE MEDICINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-STEM CELL-BASED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-STEM CELL-BASED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEM CELL-BASED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DENDRITIC CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DENDRITIC CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DENDRITIC CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NATURAL KILLER (NK) CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NATURAL KILLER (NK) CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NATURAL KILLER (NK) CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-IMMUNE CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-IMMUNE CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-IMMUNE CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL-BASED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL-BASED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL-BASED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EXTRACELLULAR & ACELLULAR THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EXTRACELLULAR & ACELLULAR THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EXTRACELLULAR & ACELLULAR THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE TRANSFER VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE TRANSFER VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE TRANSFER VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA & DNA-BASED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA & DNA-BASED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA & DNA-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOMATERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOMATERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOMATERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NATURAL BIOMATERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NATURAL BIOMATERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NATURAL BIOMATERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYNTHETIC BIOMATERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SYNTHETIC BIOMATERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYNTHETIC BIOMATERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GROWTH FACTORS & CYTOKINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GROWTH FACTORS & CYTOKINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GROWTH FACTORS & CYTOKINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SCAFFOLDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SCAFFOLDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SCAFFOLDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANGIOGENESIS & VASCULAR REGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANGIOGENESIS & VASCULAR REGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANGIOGENESIS & VASCULAR REGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONGENITAL HEART DEFECT REPAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CONGENITAL HEART DEFECT REPAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONGENITAL HEART DEFECT REPAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEART VALVE REPLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEART VALVE REPLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEART VALVE REPLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL AESTHETIC PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL AESTHETIC PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL AESTHETIC PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BURN TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BURN TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BURN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHRONIC WOUND HEALING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CHRONIC WOUND HEALING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHRONIC WOUND HEALING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BETA CELL TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BETA CELL TRANSPLANTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BETA CELL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ISLET CELL REGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ISLET CELL REGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ISLET CELL REGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ALZHEIMER'S TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ALZHEIMER'S TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ALZHEIMER'S TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MULTIPLE SCLEROSIS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MULTIPLE SCLEROSIS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MULTIPLE SCLEROSIS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PARKINSON'S THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PARKINSON'S THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PARKINSON'S THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SPINAL CORD INJURY REPAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SPINAL CORD INJURY REPAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SPINAL CORD INJURY REPAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL STROKE RECOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL STROKE RECOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL STROKE RECOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL TUMOR ABLATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CORNEAL REPAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CORNEAL REPAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CORNEAL REPAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL RETINAL REGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL RETINAL REGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL RETINAL REGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORTHOPEDIC & MUSCULOSKELETAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ORTHOPEDIC & MUSCULOSKELETAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORTHOPEDIC & MUSCULOSKELETAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BONE REGENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BONE REGENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BONE REGENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL TENDON REPAIR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL TENDON REPAIR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL TENDON REPAIR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. GCC REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. GCC REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. GCC REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. GCC REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 313. GCC REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 314. GCC REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. GCC REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 316. GCC REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 317. GCC REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 318. GCC REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 319. GCC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 320. GCC REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 321. GCC REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. GCC REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 323. GCC REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. GCC REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. GCC REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 326. GCC REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 327. GCC REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 334. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 347. BRICS REGENERATIVE MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 350. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 351. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2032 (USD MILLION)
  • TABLE 352. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 353. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2032 (USD MILLION)
  • TABLE 354. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 355. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2032 (USD MILLION)
  • TABLE 356. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 357. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AR